News Contact Us

Japan approves AstraZeneca's lung cancer treatment, Tagrisso

Author : Saipriya Iyer | Published Date : 2018-08-22 

AstraZeneca, a global biopharmaceutical company has reportedly announced the approval of its new lung cancer treatment, Tagrisso by the Japanese Ministry of Health, Labor and Welfare. As per reliable sources, the treatment would be available for the first line treatment of patients suffering from incurable or recurring epidermal growth factor receptor (EGFR).

According to an official press release by AstraZeneca, the approval comes on the heels of the global Phase III FLAURA trial results which were reportedly conducted on numerous Japanese patients. Incidentally, Tagrisso’s safety data in the FLAURA trial is in line with the results observed in prior clinical trials.

As per Dave Fredrickson, Executive VP and Head of AstraZeneca’s Oncology Business Unit, their Tagrisso lung cancer treatment has already been approved by Japan for specifically treating patients with EGFR mutation, which apparently is resistant to the existing 1st-line EGFR-inhibitor medicines.

Fredrickson added that the new approval would promote the use of Tagrisso to the 1st-line setting, eventually replacing older medicines, irrespective of Japan’s high prevalence of EGFR mutation, and would offer a vital treatment alternative.

Reports suggest that the FLAURA trial revealed a superior progression free survival benefit which was consistent across all subgroups including in patients with or without the central nervous system (CNS) metacases, a significant benefit for lung cancer patients.

According to official reports, AstraZeneca's new products progressively provided a boost to the company, helping profits beat the firm’s estimates in the second quarter. Sources also claim that Pascal Soriot, CEO of AstraZeneca was reportedly encountered selling the rights of some medicines in a bid to expedite the company’s revenue and support its new medical research.

Recent reports claim that Tagrisso has received approvals in close to 40 countries for the 1st-line treatment of patients suffering with metastatic EGFRm NSCLC, including the U.S. and Europe.

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Ramping production of lithium-ion batteries to accelerate tert-amylbenzene demand in Asia Pacific

Published Date: 2021-01-05         Author: Saipriya Iyer

As an active pharmaceutical ingredient (API) used in various clinical products to being used as an electronic additive in the making of lithium-ion batteries, tert amylbenzene (TAB) has gained wide-spread recognition across diverse industries. The chemical substance acts as a crucial intermediate in... Read More

FMCG firms to explore oral care market amidst rising hygiene concerns

Published Date: 2021-01-04         Author: Saipriya Iyer

Fast-moving consumer goods businesses in India are reportedly expanding their range of oral care, joining new and niche categories including mouthwashes, ayurvedic mouth cleansers, and mouth sprays as customer issues around general hygiene persists. For the record, Dabur India and Colgate Palmoli... Read More

Microsoft to introduce ‘Google assistant’ alternative for Windows

Published Date: 2020-12-28         Author: Saipriya Iyer

Microsoft Corporation, an American multinational technology giant, is reportedly testing a new voice launcher feature which will enable users to interact with files and applications using voice commands. According to trusted sources, the feature is currently available to select group of users who... Read More

© 2021 Fractovia. All Rights Reserved